



Significant Breakthrough in Building its Nucleic Acid Innovative Drug Platform

NEW YORK and SYDNEY, Australia, 21 July, 2025 - Beroni Group (NSX: BTG) ("Beroni" or the "Company"), advises that its wholly owned subsidiary, Beroni Pharmaceuticals (Guangdong) Co., Ltd., has recently achieved a significant breakthrough in building its nucleic acid innovative drug platform. This includes developing a proprietary liposome nanoparticle (LNP) delivery formulation process that stands independent from industry leaders like Moderna and CureVac, which dominate the nucleic acid drug sector.

Additionally, the Company has made significant progress in researching and developing nucleic acid drugs for metabolic-associated steatotic liver disease (MASLD), metabolic-associated steatohepatitis (MASH), and liver fibrosis. All preclinical studies have now been completed, and the Company is gearing up for Investigational New Drug (IND) registration.

Nucleic Acid Contract Research Organization (CRO) Service Platform

Building on this, Beroni Pharmaceuticals is launching a nucleic acid drug CRO service platform to provide specialized research and development support to companies developing nucleic acid drugs. This platform focuses on providing or developing advanced targeted liposome-aptamer complexes and multi-target small nucleic acid drugs at the organ, tissue, and cellular levels for our partners. Our nucleic acid drug delivery system can be customized to meet specific partner needs, creating tailored delivery vehicles that precisely transport nucleic acid therapeutics into diseased cells. This enhances treatment efficacy while minimizing off-target effects. Whether you're advancing research or clinical applications, our customizable CRO solutions integrate cutting-edge nucleic acid aptamer technology with lipid nanoparticle (LNP) systems to enable safe and efficient drug delivery.

Below is a detailed overview of our primary services, designed to address specific therapeutic needs in fields like cardiology, hepatology, and oncology. Each service encompasses design, synthesis, modification, purification, and testing to guarantee optimal performance.

Cardiology-Specific Small Nucleic Acid Drugs (Cell + Gene Targeting)

We offer or develop small nucleic acid drugs specifically targeting cardiomyocytes, combining cell-specific aptamers with gene-targeting agents (such as ASO, siRNA, or miRNA). This dual-targeting approach ensures precise regulation of pathological genes within cardiomyocytes, making it suitable for treating cardiovascular diseases.

Cardiology-Specific Targeted Lipid Nanoparticle (LNP) Drug Delivery Tools

Our lipid nanoparticles (LNPs), modified with cardiac-specific aptamers, can deliver mRNA or small-molecule drugs directly into the cytoplasm of cardiac cells. This technology supports the treatment of heart-related diseases through efficient, non-invasive intracellular delivery.

Liver Organ or Hepatic Stellate Cell (HSC)-Specific Small Nucleic Acid Drugs (Cell + Gene Targeting)

Designed for specific targeting of the liver organ, tissues, or even pathological liver cells, we provide small nucleic acid drugs that combine hepatic stellate cell (HSC)-specific aptamers with gene-targeted therapies. This service emphasizes synthesis, modification, and validation for liver diseases, ensuring high specificity and therapeutic impact.

Hepatic Stellate Cell (HSC)-Targeted Lipid Nanoparticle (LNP) Drug Delivery Tools

These aptamer-modified lipid nanoparticles (LNPs) deliver mRNA or small-molecule drugs into the cytoplasm of hepatic stellate cells, offering a powerful tool for conditions like liver cirrhosis. The system promotes targeted therapy while reducing systemic side effects.

Dendritic Cell (DC)-Specific Small Nucleic Acid Drugs (Cell + Gene Targeting)

We provide small nucleic acid drugs that specifically target dendritic immune cells (DCs), integrating cell-specific aptamers with gene-regulating agents (such as ASO, siRNA, or miRNA). This enables precise immune cell engineering, supporting applications in immunotherapy and vaccine development.

DC-Targeted Lipid Nanoparticle (LNP) Drug Delivery Tools

Modified with dendritic cell (DC)-specific aptamers, our LNPs facilitate the delivery of mRNA or small-molecule drugs into the cytoplasm of dendritic cells (DCs). This is particularly useful for constructing tumor vaccines, as it enhances the host's immune response through precise DC targeting.

Customized R&D and Manufacturing Services for Specific Organ, Tissue, or Cellular-Level Targeted Delivery

In addition to our core services, we offer tailored product development and manufacturing for nucleic acid drugs targeting specific organs, tissues, or cells across various diseases. From initial concept to production, we ensure your project meets regulatory standards and delivers therapeutic efficacy.

Our CRO services are backed by a team of experts in nucleic acid chemistry, nanotechnology, and pharmacology, delivering reliable and scalable solutions. Please contact us to discuss how our innovative targeted therapies can accelerate your drug development process.

-End-

About Beroni Group Limited

Beroni Group is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of FDA/CE approved virus diagnostic kits, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, United States, China and Japan. It is listed on the National Stock Exchange of Australia. To learn more about Beroni, please visit www.beronigroup.com.

For more information, please contact us at:

Tel: +61 2 9159 1827

Email: enquiry@beronigroup.com

Website: www.beronigroup.com